Sucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of “Buy” from Brokerages
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been given an average rating of “Buy” by the twelve brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $17.63.
SCMP has been the subject of a number of research reports. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Leerink Swann initiated coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $15.00 target price for the company. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, ValuEngine downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd.
ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/17/sucampo-pharmaceuticals-inc-scmp-receives-consensus-recommendation-of-buy-from-brokerages.html.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 12.15 on Friday. The firm’s market capitalization is $562.85 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55. The firm’s 50-day moving average is $11.24 and its 200 day moving average is $10.69.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same period in the prior year, the firm posted $0.24 EPS. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities research analysts anticipate that Sucampo Pharmaceuticals will post $1.02 EPS for the current year.
In other Sucampo Pharmaceuticals news, insider Jones W. Bryan acquired 4,700 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was bought at an average cost of $10.60 per share, with a total value of $49,820.00. Following the acquisition, the insider now owns 4,700 shares in the company, valued at $49,820. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in Sucampo Pharmaceuticals by 22.9% in the 1st quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 4,615 shares during the period. AlphaMark Advisors LLC boosted its holdings in Sucampo Pharmaceuticals by 25.4% in the 2nd quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 19,900 shares during the period. Virginia Retirement Systems ET AL bought a new position in Sucampo Pharmaceuticals in the 1st quarter worth approximately $536,000. Bank of New York Mellon Corp boosted its holdings in Sucampo Pharmaceuticals by 107.3% in the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its holdings in Sucampo Pharmaceuticals by 62.0% in the 1st quarter. Cornerstone Capital Management Holdings LLC. now owns 425,200 shares of the biopharmaceutical company’s stock worth $4,676,000 after buying an additional 162,800 shares during the period. 55.44% of the stock is owned by institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.